A comprehensive catalogue of functional genetic variations in the EGFR pathway: Protein-protein interaction analysis reveals novel genes and polymorphisms important for cancer research

International Journal of Cancer

Volumn 125, Issue 6, 2009, Pages 1257-1265

  Savas, Sevtap ^a,c   Geraci, Joseph ^a   Jurisica, Igor ^a,b   Liu, Geoffrey ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

Cancer treatment response and prognosis; EGFR pathway; Network based target selection; Protein protein interactions; SNPs

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE FYN; PROTEIN KINASE LCK;

AMINO ACID SEQUENCE; ARTICLE; CANCER RESEARCH; COMPUTER MODEL; CONTROLLED STUDY; DATA BASE; GENE FUNCTION; GENE INTERACTION; GENETIC VARIABILITY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PROTEIN INTERACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

COMPUTATIONAL BIOLOGY; GENOME, HUMAN; HUMANS; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN INTERACTION MAPPING; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 68249142895     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24535     Document Type: Article

References (80)

1. Pal SK, Pegram M. Epidermal growth factor receptor and signal transduction: potential targets for anti-cancer therapy. Anticancer Drugs 2005;16:483-94.
2. Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 2006;12: 5268-72.
3. Rocha-Lima CM, Soares HP, Raez LE, Singal R. EGFR targeting of solid tumors. Cancer Control 2007;14:295-304.
4. Jackson C, Cunningham D. A retrospective on the inhibition of epidermal growth factor receptor as a therapeutic strategy for patients with relapsed metastatic colorectal cancer: impact on treatment of today's patients. Clin Colorectal Cancer 2007;Suppl 1:S8-15.
5. Voelzke WR, Petty WJ, Lesser GJ. Targeting the epidermal growth factor receptor in high-grade astrocytomas. Curr Treat Options Oncol 2008;9:23-31.
6. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007;1773:1263-84.
7. Stephens P, Hunter C, Bignell G, Edkins S, Davies H, Teague J, Stevens C, O'Meara S, Smith R, Parker A, Barthorpe A, Blow M, et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 2004;431:525-6.
8. Milanezi F, Carvalho S, Schmitt FC. EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy. Expert Rev Mol Diagn 2008;8:417-34.
9. Soung YH, Lee JW, Kim SY, Wang YP, Jo KH, Moon SW, Park WS, Nam SW, Lee JY, Yoo NJ, Lee SH. Somatic mutations of the ERBB4 kinase domain in human cancers. Int J Cancer 2006;118: 1426-9.
10. Naoki K, Chen TH, Richards WG, Sugarbaker DJ, Meyerson M. Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res 2002;62:7001-3.
11. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, Roth JA, Albelda SM, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002;62:6997-7000.
12. Jiang BH, Liu LZ. PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochim Biophys Acta 2008;1784:150-8.
13. Marks JL, McLellan MD, Zakowski MF, Lash AE, Kasai Y, Broderick S, Sarkaria IS, Pham D, Singh B, Miner TL, Fewell GA, Fulton LL, et al. Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. PLoS ONE 2007;2:e426.
14. Marks JL, Gong Y, Chitale D, Golas B, McLellan MD, Kasai Y, Ding L, Mardis ER, Wilson RK, Solit D, Levine R, Michel K, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res 2008;68:5524-8.
15. Song JI, Grandis JR. STAT signaling in head and neck cancer. Oncogene 2000;19:2489-95.
16. Chen DJ, Nirodi CS. The epidermal growth factor receptor: a role in repair of radiation-induced DNA damage. Clin Cancer Res 2007; 13(22 Part 1):6555-60.
17. Masuda M, Toh S, Koike K, Kuratomi Y, Suzui M, Deguchi A, Komiyama S, Weinstein IB. The roles of JNK1 and Stat3 in the response of head and neck cancer cell lines to combined treatment with all-trans-retinoic acid and 5-fluorouracil. Jpn J Cancer Res 2002; 93:329-39.
18. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 2007;98:1817-24.
19. Bussink J, van der Kogel AJ, Kaanders JH. Activation of the PI3-K/ AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol 2008;9:288-96.
20. Chung CH, Ely K, McGavran L, Varella-Garcia M, Parker J, Parker N, Jarrett C, Carter J, Murphy BA, Netterville J, Burkey BB, Sinard R, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006;24:4170-6.
21. Schmitz KJ, Wohlschlaeger J, Lang H, Sotiropoulos GC, Malago M, Steveling K, Reis H, Cicinnati VR, Schmid KW, Baba HA. Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol 2008;48:83-90.
22. Giatromanolaki A, Koukourakis MI, O'Byrne K, Kaklamanis L, Dicoglou C, Trichia E, Whitehouse R, Harris AL, Gatter KC. Non-small cell lung cancer: c-erbB-2 overexpression correlates with low angiogenesis and poor prognosis. Anticancer Res 1996;16:3819-25.
23. Chakravarti A. Population genetics-making sense out of sequence. Nat Genet 1999;21(1 Suppl):56-60.
24. Erichsen HC, Chanock SJ. SNPs in cancer research and treatment. Br J Cancer 2004;90:747-51.
25. Belle DJ, Singh H. Genetic factors in drug metabolism. Am Fam Physician 2008;77:1553-60.
26. Yoon SM, Hong YC, Park HJ, Lee JE, Kim SY, Kim JH, Lee SW, Park SY, Lee JS, Choi EK. The polymorphism and haplotypes of XRCC1 and survival of non-small-cell lung cancer after radiotherapy. Int J Radiat Oncol Biol Phys 2005;63:885-91.
27. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, FitzHugh W, Funke R, Gage D, et al. Initial sequencing and analysis of the human genome. Nature 2001; 409:860-921.
28. Miller RD, Kwok PY. The birth and death of human single-nucleotide polymorphisms: new experimental evidence and implications for human history and medicine. Hum Mol Genet 2001;10:2195-8.
29. Chorley BN, Wang X, Campbell MR, Pittman GS, Noureddine MA, Bell DA. Discovery and verification of functional single nucleotide polymorphisms in regulatory genomic regions: current and developing technologies. Mutat Res 2008;659:147-57.
30. Jacobson EM, Concepcion E, Oashi T, Tomer Y. A Graves' disease-associated Kozak sequence single-nucleotide polymorphism enhances the efficiency of CD40 gene translation: a case for translational pathophysiology. Endocrinology 2005;146:2684-91.
31. Kumimoto H, Yamane Y, Ishizaki K. Two haplotypes of 50 untranslated region in L-myc gene with different internal ribosome entry site activity. Int J Oncol 2005;26:287-93.
32. Espel E. The role of the AU-rich elements of mRNAs in controlling translation. Semin Cell Dev Biol 2005;16:59-67.
33. Yu Z, Li Z, Jolicoeur N, Zhang L, Fortin Y, Wang E, Wu M, Shen SH. Aberrant allele frequencies of the SNPs located in microRNA target sites are potentially associated with human cancers. Nucleic Acids Res 2007;35:4535-41.
34. Hudder A, Novak RF. miRNAs: effectors of environmental influences on gene expression and disease. Toxicol Sci 2008;103:228-40.
35. Ng PC, Henikoff S. Predicting the effects of amino acid substitutions on protein function. Annu Rev Genomics Hum Genet 2006;7:61-80.
36. Savas S, Kim DY, Ahmad MF, Shariff M, Ozcelik H. Identifying functional genetic variants in DNA repair pathway using protein conservation analysis. Cancer Epidemiol Biomarkers Prev 2004;13:801-7.
37. Savas S, Taylor IW, Wrana JL, Ozcelik H. Functional nonsynonymous single nucleotide polymorphisms from the TGF-beta protein interaction network. Physiol Genomics 2007;29:109-17.
38. Stalder L, Muhlemann O. The meaning of nonsense. Trends Cell Biol 2008;18:315-21.
39. Savas S, Tuzmen S, Ozcelik H. Human SNPs resulting in premature stop codons and protein truncation. Hum Genomics 2006; 2:274-86.
40. Oda K, Matsuoka Y, Funahashi A, Kitano H. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol 2005;1:2005 0010.
41. Ohtsu H, Dempsey PJ, Eguchi S. ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors. Am J Physiol Cell Physiol 2006;291:C1-10.
42. Zhong L, Zhao W, Wu J, Li B, Zolotukhin S, Govindasamy L, Agbandje-McKenna M, Srivastava A. A dual role of EGFR protein tyrosine kinase signaling in ubiquitination of AAV2 capsids and viral second-strand DNA synthesis. Mol Ther 2007;15:1323-30.
43. Conpath EGFR1 signaling pathway. Available at: http://conpath.dnachip. co.jp/search/pathway-detail.php/CNPTH010009.
44. Sigma Aldrich EGFR pathway. Available at: http://www.sigmaaldrich. com/Area-of-Interest/Life-Science/Cell-Signaling/Scientific-Resources/ Pathway-Slides---Charts/EGF-Receptor-Signal-Transduction-Pathway. html.
45. Cancer cell map. Available at: http://cancer.cellmap.org/cellmap/ record.do?id5356.
46. Wheeler DL, Barrett T, Benson DA, Bryant SH, Canese K, Chetvernin V, Church DM, Dicuccio M, Edgar R, Federhen S, Feolo M, Geer LY, et al. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 2008;36(Database issue): D13-21.
47. Bruford EA, Lush MJ, Wright MW, Sneddon TP, Povey S, Birney E. The HGNC database in 2008: a resource for the human genome. Nucleic Acids Res 2008;36(Database issue):D445-8.
48. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, Sirotkin K. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 2001;29:308-11.
49. Kim BC, Kim WY, Park D, Chung WH, Shin KS, Bhak J. SNP@ Promoter: a database of human SNPs (single nucleotide polymorphisms) within the putative promoter regions. BMC Bioinformatics 2008;Suppl 1:S2.
50. Bao L, Zhou M, Wu L, Lu L, Goldowitz D, Williams RW, Cui Y. PolymiRTS database: linking polymorphisms in microRNA target sites with complex traits. Nucleic Acids Res 2007;35(Database issue): D51-4.
51. Ramensky V, Bork P, Sunyaev S. Human non-synonymous SNPs: server and survey. Nucleic Acids Res 2002;30:3894-900.
52. Mulder N, Apweiler R. InterPro and InterProScan: tools for protein sequence classification and comparison. Methods Mol Biol 2007;396: 59-70.
53. Mignone F, Grillo G, Licciulli F, Iacono M, Liuni S, Kersey PJ, Duarte J, Saccone C, Pesole G. UTRdb and UTRsite: a collection of sequences and regulatory motifs of the untranslated regions of eukaryotic mRNAs. Nucleic Acids Res 2005;33(Database issue): D141-6.
54. Brown KR, Jurisica I. Online predicted human interaction database. Bioinformatics 2005;21:2076-82.
55. NAVIGaTOR. Available at:http://ophid.utoronto.ca/navigator.
56. O'Donovan C, Martin MJ, Gattiker A, Gasteiger E, Bairoch A, Apweiler R. High-quality protein knowledge resource: SWISS-PROT and TrEMBL. Brief Bioinform 2002;3:275-84.
57. Savas S, Ahmad MF, Shariff M, Kim DY, Ozcelik H. Candidate nsSNPs that can affect the functions and interactions of cell cycle proteins. Proteins 2005;58:697-705.
58. Khajavi M, Inoue K, Lupski JR. Nonsense-mediated mRNA decay modulates clinical outcome of genetic disease. Eur J Hum Genet 2006;14:1074-81.
59. Puyo S, Le Morvan V, Robert J. Impact of EGFR gene polymorphisms on anticancer drug cytotoxicity in vitro. Mol Diagn Ther 2008; 12:225-34.
60. Liu G, Gurubhagavatula S, Zhou W, Wang Z, Yeap BY, Asomaning K, Su L, Heist R, Lynch TJ, Christiani DC. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. Pharmacogenomics J 2008;8: 129-38.
61. Papadopoulou E, Tripsianis G, Anagnostopoulos K, Tentes I, Kakolyris S, Galazios G, Sivridis E, Simopoulos K, Kortsaris A. The influence of serum HER-2 levels and HER-2 codon 655 polymorphism on breast cancer outcome. Neoplasma 2008;55:113-21.
62. Hamai Y. Matsumura S, Matsusaki K, Kitadai Y, Yoshida K, Yamaguchi Y, Imai K, Nakachi K, Toge T, Yasui W. A single nucleotide polymorphism in the 50 untranslated region of the EGF gene is associated with occurrence and malignant progression of gastric cancer. Pathobiology 2005;72:133-8.
63. Lanuti M, Liu G, Goodwin JM, Zhai R, Fuchs BC, Asomaning K, Su L, Nishioka NS, Tanabe KK, Christiani DC. A functional epidermal growth factor (EGF) polymorphism. EGF serum levels, and esophageal adenocarcinoma risk and outcome. Clin Cancer Res 2008;14: 3216-22.
64. Ostareck-Lederer A, Ostareck DH, Standart N, Thiele BJ. Translation of 15-lipoxygenase mRNA is inhibited by a protein that binds to a repeated sequence in the 3′ untranslated region. EMBO J 1994;13: 1476-81.
65. Rajasekaran R, Doss GP, Sudandiradoss C, Ramanathan K, Rituraj P, Sethumadhavan R. Computational and structural investigation of deleterious functional SNPs in breast cancer BRCA2 gene. Sheng Wu Gong Cheng Xue Bao 2008;24:851-6.
66. Shen J, Deininger PL, Zhao H. Applications of computational algorithm tools to identify functional SNPs in cytokine genes. Cytokine 2006;35:62-6.
67. Frischmeyer PA, Dietz HC. Nonsense-mediated mRNA decay in health and disease. Hum Mol Genet 1999;8:1893-900.
68. Xu Y, Seet LF, Hanson B, Hong W. The Phox homology (PX) domain, a new player in phosphoinositide signalling. Biochem J 2001;360 (Part 3):513-30.
69. Vollert CS, Uetz P. The phox homology (PX) domain protein interaction network in yeast. Mol Cell Proteomics 2004;3:1053-64.
70. Lee CS, Kim IS, Park JB, Lee MN, Lee HY, Suh PG, Ryu SH. The phox homology domain of phospholipase D activates dynamin GTPase activity and accelerates EGFR endocytosis. Nat Cell Biol 2006;8:477-84.
71. Bork P. Hundreds of ankyrin-like repeats in functionally diverse proteins: mobile modules that cross phyla horizontally? Proteins 1993; 17:363-74.
72. Moore JH. The ubiquitous nature of epistasis in determining susceptibility to common human diseases. Hum Hered 2003;56:73-82.
73. Rosen EM, Fan S, Isaacs C. BRCA1 in hormonal carcinogenesis: basic and clinical research. Endocr Relat Cancer 2005;12:533-48.
74. Tischkowitz MD, Foulkes WD. The basal phenotype of BRCA1-related breast cancer: past, present and future. Cell Cycle 2006;5:963-7.
75. Fischgrabe J, Wulfing P. Targeted therapies in breast cancer: established drugs and recent developments. Curr Clin Pharmacol 2008;3: 85-98.
76. Chen HY, Yu SL, Chen CH, Chang GC, Chen CY, Yuan A, Cheng CL, Wang CH, Terng HJ, Kao SF, Chan WK, Li HN, et al. A fivegene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007;356:11-20.
77. Lau SK, Boutros PC, Pintilie M, Blackhall FH, Zhu CQ, Strumpf D, Johnston MR, Darling G, Keshavjee S, Waddell TK, Liu N, Lau D, et al. Three-gene prognostic classifier for early-stage non small-cell lung cancer. J Clin Oncol 2007;25:5562-9.
78. Thomas DC. The need for a systematic approach to complex pathways in molecular epidemiology. Cancer Epidemiol Biomarkers Prev 2005;14:557-9.
79. Onay VU, Briollais L, Knight JA, Shi E, Wang Y, Wells S, Li H, Rajendram I, Andrulis IL, Ozcelik H. SNP-SNP interactions in breast cancer susceptibility. BMC Cancer 2006;6:114.
80. Bochdanovits Z, Sondervan D, Perillous S, van Beijsterveldt T, Boomsma D, Heutink P. Genome-wide prediction of functional gene-gene interactions inferred from patterns of genetic differentiation in mice and men. PLoS ONE 2008;3:e1593.